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A B S T R A C T
Purpose
We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as
first-line therapy for patients with advanced breast cancer (BC) to evaluate progression-free
survival (PFS) for nab-paclitaxel or ixabepilone versus paclitaxel.
Patients and Methods
Eligible patients were age  18 years with chemotherapy-naive advanced BC. Patients were
randomly assigned to bevacizumab with paclitaxel 90 mg/m2 (arm A), nab-paclitaxel 150 mg/m2
(arm B), or ixabepilone 16 mg/m2 (arm C), once per week for 3 of 4 weeks. Planned enrollment was
900 patients, which would give 88% power to detect a hazard ratio of 0.73.
Results
In all, 799 patients were enrolled, and 783 received treatment (97% received bevacizumab). Arm C was
closed for futility at the first interim analysis (n  241), and arm A (n  267) and arm B (n  275) were closed
for futility at the second interim analysis. Median PFS for paclitaxel was 11 months, ixabepilone was inferior
to paclitaxel (PFS, 7.4 months; hazard ratio, 1.59; 95% CI, 1.31 to 1.93; P  .001), and nab-paclitaxel was
not superior to paclitaxel (PFS, 9.3 months; hazard ratio, 1.20; 95% CI, 1.00 to 1.45; P  .054). Results were
concordant with overall survival; time to treatment failure was significantly shorter in both experimental
arms v paclitaxel. Hematologic and nonhematologic toxicity, including peripheral neuropathy, was increased
with nab-paclitaxel, with more frequent and earlier dose reductions.
Conclusion
In patients with chemotherapy-naive advanced BC, ixabepilone once per week was inferior to
paclitaxel, and nab-paclitaxel was not superior with a trend toward inferiority. Toxicity was
increased in the experimental arms, particularly for nab-paclitaxel. Paclitaxel once per week
remains the preferred palliative chemotherapy in this setting.
J Clin Oncol 33:2361-2369. © 2015 by American Society of Clinical Oncology
INTRODUCTION
Metastatic breast cancer (BC) is generally incurable
with few patients achieving long-term disease-free
survival.1 Despite a marked increase in the choice of
active agents, the impact on overall survival (OS) has
been modest.2,3
Paclitaxel is a taxane derivative and is among
the most active agents in the treatment of BC.4 Ran-
domized trials based on mathematical modeling
compared dosing once per week with dosing once
every 3 weeks in advanced disease, demonstrating
improved efficacy and reduced hematologic toxic-
ity.5,6 The Eastern Cooperative Oncology Group
(ECOG) 2100 (Paclitaxel With or Without Bevaci-
zumab in Treating Patients With Locally Recurrent
or Metastatic Breast Cancer) trial compared pacli-
taxel alone once per week or in combination with
the vascular endothelial growth factor (VEGF) anti-
body bevacizumab as first-line therapy, with near
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doubling of progression-free survival (PFS) in patients receiving bev-
acizumab7 and only minimal impact on OS.
One major limitation of paclitaxel is its poor water solubility;
thus it requires Cremophor EL as a solvent. Nab-paclitaxel is a solvent-
free novel formulation of paclitaxel in albumin-bound nanoparticles,
which eliminates the need for premedication to prevent hypersensi-
tivity.8 Nab-paclitaxel 260 mg/m2 once every 3 weeks was superior to
paclitaxel 175 mg/m2 with less hematologic toxicity but increased
peripheral neuropathy.9 Once-per-week dosing at 100 and 125 mg/m2
was found to be efficacious, with minimal toxicity in taxane-resistant
disease.10 A randomized first-line phase II trial reported improved PFS
and OS with once-per-week dosing with nab-paclitaxel 150 mg/m2
compared with nab-paclitaxel 100 mg/m2, with only slightly higher
rates of peripheral neuropathy.11
Ixabepilone is a semisynthetic analog of epothilone B that binds
to the same beta-tubulin site as paclitaxel and, in preclinical models, is
a more potent tubulin polymerizer.12,13 Ixabepilone once every 3
weeks with capecitabine was superior to capecitabine alone in taxane-
resistant disease,14 and as a single agent, it demonstrated efficacy in
multidrug-resistant metastatic BC.15-17 Its use is complicated by sig-
nificant peripheral neuropathy and bone marrow suppression. Single-
arm trials and randomized phase II studies suggested reduced toxicity
with ixabepilone once per week at doses up to 16 mg/m2.18-24
To determine the optimal therapy for patients with chemotherapy-
naive advanced BC, we designed a randomized phase III trial compar-
ing either nab-paclitaxel or ixabepilone once per week to paclitaxel
once per week. All agents were given in combination with bevaci-
zumab. The paclitaxel and bevacizumab schedule mirrored the sched-
ule in ECOG 2100; the doses for nab-paclitaxel and ixabepilone were
chosen on the basis of data from phase II trials. The hypotheses tested
were that newer antimicrotubule agents would offer improved PFS
with similar or reduced toxicity compared with standard paclitaxel.
PATIENTS AND METHODS
Study Design and Procedures
The Cancer and Leukemia Group B (CALGB) 40502 (Paclitaxel, Nab-
Paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients
With Stage IIIC or Stage IV Breast Cancer) trial was a three-arm randomized
phase III trial comparing paclitaxel once per week to nanoparticle albumin-
bound nab-paclitaxel once per week and to ixabepilone as first-line chemo-
therapy with bevacizumab for locally recurrent or metastatic BC. The study
was approved by the National Cancer Institute’s Institutional Review Board,
and all patients signed approved informed consent before registration and
screening. All chemotherapy was administered once per week on days 1, 8, and
15 followed by 1 week of rest with 28-day treatment cycles. Treatment arms
were paclitaxel 90 mg/m2 (arm A), nab-paclitaxel 150 mg/m2 (arm B), and
ixabepilone 16 mg/m2 (arm C). Bevacizumab was given at 10 mg/kg on days 1
and 15 of each cycle until March 2011, when an amendment allowed optional
use to be declared at the time of random assignment. Standard premedications
were recommended for paclitaxel and ixabepilone.
Data quality was ensured by review of the data by the Alliance Statistics
and Data Center and by the study chairperson who adhered to Alliance poli-
cies. This phase III therapeutic trial was monitored at least twice annually by
the Data and Safety Monitoring Board, a standing committee composed of
individuals from within and outside the Alliance.
Eligibility
Eligibility included patients age  18 years with histologically docu-
mented stage IV or stage IIIC BC not amenable to local therapy, ECOG
performance status of 0 to 1, and life expectancy  12 weeks. No prior
chemotherapy for metastatic disease or prior treatment with bevacizumab was
allowed; patients could have received any number of prior hormone therapies.
Prior taxane therapy in the adjuvant/neoadjuvant setting was allowed if met-
astatic disease occurred  12 months after the last dose of taxane. Patients with
human epidermal growth factor receptor 2–positive (HER2-positive) disease
were eligible if they had previously received trastuzumab or lapatinib. Major
surgery must have been completed  28 days before registration. Patients with
a history of resected brain metastases or brain radiation with stable imaging for
3 months were eligible. Measurable disease and adequate bone marrow, renal,
and hepatic function were required.
Exclusion criteria included grade  2 pre-existing peripheral neuropa-
thy, prior grade  3 hypersensitivity to paclitaxel or Cremophor EL, history of
uncontrolled hypertension, recent GI fistula or perforation, recent significant
bleeding, a history of significant cardiovascular disease, nonhealing wounds,
or bone fracture.
Dose Modifications
Dose levels and selected modifications are outlined in Appendix Table
A1 (online only); re-escalation was not allowed. Use of granulocyte colony-
stimulating factor was allowed at the physician’s discretion. If treatment was
delayed for more than 4 weeks, chemotherapy was discontinued. Patients
whose disease had not progressed by cycle 7 were allowed to discontinue
chemotherapy and continue treatment with bevacizumab alone.
Evaluation of Response
Tumor imaging was repeated every two cycles; responses required
4-week confirmation. Response was assessed by using RECIST 1.0.
Statistics
The primary objective was to test the efficacy of nab-paclitaxel versus
paclitaxel (control arm) and ixabepilone versus paclitaxel in combination with
bevacizumab in patients with advanced BC. The primary end point was PFS
defined as the interval from date of registration until date of first disease
progression or death as a result of any cause; patients were censored at the last
date they were assessed to be progression free. Secondary objectives included
the same comparisons for OS: 12-month rate of progression, objective re-
sponse rate, duration of response, and time to treatment failure defined as the
interval from registration until termination of protocol therapy for any reason.
Toxicity end points included adverse events and a comparison of grade greater
than 2 sensory neuropathy by using Common Terminology Criteria for Ad-
verse Events version 4.0. Embedded correlative studies of tumor and blood
biomarkers, pharmacogenomics, health disparities, and quality of life will be
reported in separate analyses.
Target accrual was 900 patients randomly assigned 1:1:1 and stratified by
prior use of adjuvant taxane, hormone receptor status, and optional use of
bevacizumab. Final analysis after 715 PFS events gave 88% power to detect a
prolongation of PFS from 11 months in the control arm to 15 months in each
experimental arm.
Interim monitoring for superiority and futility was performed separately
for nab-paclitaxel and ixabepilone. Under Lan-DeMets error spending func-
tions,25 boundaries for superiority required a 99% predictive probability that
final analysis would conclude efficacy,26 and boundaries for futility were de-
fined by Freidlin et al.27
The primary assessments of efficacy used stratified log-rank tests28 with
one-sided   .0135 for each comparison established by using the method of
Jung.29 Secondary analysis of efficacy used multivariable Cox proportional
hazards models with known prognostic factors. Time-to-event end points
were summarized by using Kaplan and Meier estimates.30 Rates of objec-
tive response and adverse events were compared between arms by using
Fisher’s exact test.31 For each experimental arm, comparisons with patients
concurrently randomly assigned to the control arm were performed under
modified intention-to-treat, excluding only those who never began proto-
col treatment. Statistical analyses were performed by using SAS v9.2 (SAS
Institute, Cary, NC) and R 2.15.1 (http://www.r-project.org) and were
conducted by the Alliance Statistics and Data Center.
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RESULTS
The study was activated in October 2008 and was closed to accrual in
November 2011. In March 2011, an amendment allowed optional use
of bevacizumab declared before random assignment. After a first
planned interim analysis at 165 PFS events, ixabepilone crossed the
futility boundary for superiority. On the basis of Data and Safety
Monitoring Board recommendations, the ixabepilone arm was closed
on July 8, 2011, and accrual continued to the paclitaxel and nab-
paclitaxel arms with equally weighted random assignment. At the
second planned interim analysis at 236 PFS events, the nab-paclitaxel
arm crossed the futility boundary for superiority and was closed on
November 30, 2011. Statistical analyses were performed on all data
available as of June 4, 2013.
Patient and Disease Characteristics
In all, 799 patients were enrolled and randomly assigned; 16 did
not start treatment: eight were randomly assigned to paclitaxel, four to
nab-paclitaxel, and four to ixabepilone (CONSORT diagram; Fig 1).
In total, 267 patients were treated with nab-paclitaxel, 241 with ixa-
bepilone, and 275 with paclitaxel (246 were concurrently enrolled in
the ixabepilone arm). At the time of reporting, 755 (96%) had stopped
study therapy; 437 patients (56%) had died, 29 (4%) withdrew con-
sent to be observed, and one ( 1%) was lost to follow-up. The
median follow-up for all surviving patients was 25 months, with a
maximum of 50 months. The majority of patients received protocol-
specified bevacizumab, with only 20 (3%) electing not to receive
bevacizumab after the issuance of the amendment allowing optional
use. Therefore, strata defined by bevacizumab use were excluded from
statistical analyses.
Patient characteristics were well balanced between study arms
(Table 1). Median age was 57 years, 99% were female, and 80% were
white. Forty-four percent received taxanes as adjuvant therapy, 72%
(n  573) had hormone receptor–positive disease, 25% (n  201) had
triple-negative BC (TNBC) tumors (estrogen receptor–negative/pro-
gesterone receptor–negative/HER2-negative), and 2% (n  20) had
HER2-positive disease. Among treated patients, 56% had a disease-
free interval (DFI) from diagnosis of primary tumor to diagnosis of
metastatic disease of  2 years. Slightly more patients receiving ixa-
bepilone had bone metastases compared with patients randomly as-
signed concurrently to paclitaxel (Appendix Table A2, online only).
Efficacy
Tests of superiority of ixabepilone and of nab-paclitaxel to pacli-
taxel were deemed futile during interim monitoring of the trial. After
continued follow-up of all patients, median PFS was 11 months for
paclitaxel. In a post hoc analysis, ixabepilone was inferior to paclitaxel
with a median PFS of 7.4 months and a hazard ratio (HR) of 1.59 (95%
CI, 1.31 to 1.93; P  .001; Fig 2A). Nab-paclitaxel trended toward
inferiority to paclitaxel with a median PFS of 9.3 months and HR of
1.20 (95% CI, 1.00 to 1.45; log-rank P  .054; Fig 2B), but the post hoc
test did not reach statistical significance. A multivariable Cox propor-
tional hazards model was used to compare each experimental arm to
paclitaxel, adjusting for stratification factors, DFI of  2 years versus
more than 2 years, and presence or not of visceral metastases (Table
2). Results are concordant with log-rank tests and demonstrate the
known prognostic relationships of prior taxane use, hormone re-
ceptor negativity, shorter DFI, and visceral metastases predicting
worse PFS.
An unplanned, exploratory subset analysis of patients with TN
(Fig 3A and 3B) and hormone receptor–positive disease (Fig 3C and
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Fig 1. CONSORT diagram for the intent-to-treat analysis of data from the Cancer and Leukemia Group B (CALGB) 40502 (Paclitaxel, Nab-Paclitaxel, or Ixabepilone
With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer) trial.
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3D) was conducted. In multivariable Cox proportional hazards mod-
els with the covariates mentioned previously, ixabepilone was inferior
to paclitaxel (median PFS, 5.6 to 7.4 months; HR, 1.57; 95% CI, 1.08 to
2.29; P  .020). No significant difference was found between nab-
paclitaxel and paclitaxel (median PFS, 7.4 and 6.5 months, respec-
tively; HR, 0.86; 95% CI, 0.60 to 1.25; P  .43).
For patients with hormone receptor–positive disease, the median
PFS for paclitaxel was 12.4 months. By using a multivariable Cox
proportional hazards model for PFS, ixabepilone (median PFS, 8.0
months; HR, 1.62; 95% CI, 1.29 to 2.04; P  .001) and nab-paclitaxel
(median PFS, 10.0 months; HR, 1.45; 95% CI, 1.16 to 1.81; P  .0012)
treatments were inferior to treatment with paclitaxel.
Tumor Response
For 783 patients who began protocol treatment, the overall re-
sponse rate was 38% for paclitaxel, 34% for nab-paclitaxel, and 27%
for ixabepilone (Appendix Table A3, online only). There was no
difference in response between nab-paclitaxel and paclitaxel (odds
ratio, 0.84; P  .33), but response rates were significantly lower with
ixabepilone compared with paclitaxel (odds ratio, 0.57; P  .0038).
Time to treatment failure was significantly shorter in both experimen-
tal arms compared with paclitaxel, with a median of 4.9 months versus
6.8 months (P .001) forixabepiloneand5.2monthsversus6.6months
(P  .001) for nab-paclitaxel. On the basis of the lack of benefit in the
experimental arms, duration of response was not evaluated.
OS
By using a stratified log-rank test, a post hoc test of inferiority was
significant for ixabepilone compared with paclitaxel (median OS, 23.6
to 27.4 months; HR, 1.31; 95% CI, 1.03 to 1.66; P  .027; Fig 2C,) but
did not reach significance for nab-paclitaxel compared with paclitaxel
(median OS, 23.5 to 26.5 months; HR, 1.17; 95% CI, 0.92 to 1.47; P 
.20; Fig 2D). Multivariable analyses are consistent with univariable
tests (data not shown).
Table 1. Patient and Tumor Characteristics
Characteristic
Paclitaxel (n  283)
No. (%)
Nab-Paclitaxel (n  271)
No. (%)
Ixabepilone (n  245)
No. (%)
Total (N  799)
No. (%) P
Age, years
20-49 69 (24) 76 (28) 73 (30) 218 (27) .30
50-69 183 (66) 163 (60) 154 (63) 500 (63)
70-80 31 (11) 32 (12) 18 (7) 81 (10)
Female sex 277 (98) 268 (99) 243 (99) 788 (99) .45
Race/ethnicity
Unknown 7 (2) 4 (1) 3 (1) 14 (2)
White 220 (78) 214 (79) 206 (84) 640 (80) .23
Black 42 (15) 45 (17) 26 (11) 113 (14)
Other/unknown 14 (5) 8 (3) 10 (4) 32 (4)
Taxane as adjuvant therapy
Yes 125 (44) 120 (44) 107 (44) 352 (44) .99
No 158 (56) 151 (56) 138 (56) 447 (56)
Site of metastases
Unknown† 11 (4) 6 (2) 4 (2) 21(3)
Any visceral 217 (77) 205 (76) 199 (81) 621 (78) .35
Any soft tissue 196 (69) 184 (68) 164 (67) 544 (68) .60
Any bone 159 (56) 162 (60) 163 (67) 484 (61) .09
Disease-free interval
Unknown† 11 (4) 6 (2) 4 (2) 21 (3)
0 to  1 month (de novo) 30 (11) 31 (11) 28 (11) 89 (11) .24
 1 month to  2 years 88 (31) 87 (32) 64 (26) 239 (30)
 2 years 154 (54) 147 (54) 149 (61) 450 (56)
Clinical stage
Unknown 32 (11) 21 (8) 30 (12) 83 (10) .83
III 25 (9) 21 (8) 21 (9) 67 (8)
IV 226 (80) 229 (85) 194 (79) 649 (81)
Tumor subtype
ER or PgR unknown/missing† 8 (3) 4 (1) 4 (2) 16 (2)
ER or PgR positive 200 (71) 197 (73) 176 (72) 573 (72) .97
HER2 missing 6 (2) 6 (2) 3 (1) 15 (2)
HER2 positive 7 (2) 3 (1) 2 (1) 12 (2)
HER2 negative 187 (66) 188 (69) 171 (70) 546 (68)
ER and PgR negative 75 (27) 70 (26) 65 (27) 210 (26)
HER2 missing 1 ( 1) 4 (1) 0 (0) 5 (1)
HER2 positive 1 ( 1) 1 ( 1) 2 (1) 4 (1)
HER2 negative 73 (26) 65 (24) 63 (26) 201 (25)
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.
P values are from two-sided Fisher exact tests excluding patients for whom factors were unknown.
†Data on site of metastases, disease-free interval, and tumor subtypes were available for 778 of 783 treated patients.
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Toxicity
Toxicity information was available for 774 patients (99% of treated
patients; Table 3; Appendix Table A4, online only). Hematologic toxicity
of grade  3 occurred in 22% of patients receiving paclitaxel, 55% receiv-
ing nab-paclitaxel, and 12% receiving ixabepilone. Grade  3 nonhema-
tologic toxicity was reported in 49% of patients receiving paclitaxel, 65%
receiving nab-paclitaxel, and 58% receiving ixabepilone. Compared
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Fig 2. Kaplan-Meier plots of ixabepilone or nab-paclitaxel compared with paclitaxel, respectively, for (A, B) progression-free survival (PFS), and (C, D) overall survival
by treatment arm.
Table 2. Univariable and Multivariable Proportional Hazards Models of PFS
Variable
Comparison of Nab-Paclitaxel With Paclitaxel Comparison of Ixabepilone With Paclitaxel
HR 95% CI P HR 95% CI P
Univariable model
Treatment arm (experimental v control) 1.20 1.00 to 1.45 .054 1.59 1.31 to 1.93  .001
Multivariable factors†
Treatment arm (experimental v control) 1.22 1.01 to 1.48 .035 1.60 1.32 to 1.94  .001
Prior taxane (yes v no) 1.65 1.33 to 2.04  .001 1.46 1.18 to 1.80  .001
Hormone receptor status (negative v positive) 1.49 1.21 to 1.84  .001 1.68 1.35 to 2.07  .001
Disease-free interval ( 2 years v  2 years) 1.26 1.02 to 1.56 .036 1.21 0.98 to 1.50 .08
Visceral metastases (any v none) 1.46 1.14 to 1.85 .0023 1.17 0.91 to 1.50 .22
Abbreviations: HR, hazard ratio; PFS, progression-free survival.
Univariable models included all treated patients concurrently enrolled with each experimental arm: n  542 for nab-paclitaxel v paclitaxel; n  487 for ixabepilone
v paclitaxel.
†Multivariable models included patients with no missing information: n  537 for nab-paclitaxel v paclitaxel; n  484 for ixabepilone v paclitaxel.
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nonhematologic toxicity (P  .001 for both), and ixabepilone resulted
in less hematologic toxicity (P  .0037) and a nonsignificant trend
toward more nonhematologic toxicity (P  .14).
The most common grade 3 to 4 hematologic toxicities were
neutropenia and anemia, and the most common grade 3 to 4 nonhe-
matologic toxicities were sensory neuropathy, fatigue, hypertension,
motor neuropathy, pain, and nausea. The incidence of grade  2
sensory neuropathy was increased with nab-paclitaxel (54%) com-
pared with paclitaxel (46%; P  .031) but was similar when ixabepi-
lone (47%) was compared with paclitaxel.
Dose Reductions and Discontinuations
Dose reductions were more frequent and occurred earlier for
patients receiving nab-paclitaxel, with 31% of patients having been
dose-reduced by cycle 2, and 45% by cycle 3 compared with 9% (cycle
2) and 15% (cycle 3) for paclitaxel, and 6% (cycle 2) and 15% (cycle 3)
for ixabepilone. Only 28% of patients were still receiving full-dose
nab-paclitaxel at the start of cycle 5 compared with 76% for paclitaxel
and 65% for ixabepilone.
Discontinuation rates for chemotherapy but not for bevaci-
zumab were higher for nab-paclitaxel and ixabepilone compared with
paclitaxel. By cycle 5, 80 patients (29%) had discontinued paclitaxel,
131 (49%) nab-paclitaxel, and 120 (50%) ixabepilone.
DISCUSSION
The primary goal of treatment for patients with metastatic BC is to
diminish symptoms and control disease progression while main-
taining the highest possible quality of life. Improving OS is also a
therapeutic goal but one that has been more difficult to demon-
strate, particularly in the first-line treatment setting. Although
targeted biologic therapy offers promise for some subtypes of
metastatic BC, chemotherapy remains the backbone of systemic
therapy for hormone-resistant disease. New chemotherapy agents
offer the potential for activity in resistant disease, with similar or
improved toxicity.
The goal of this phase III cooperative group trial was to compare
two newly developed agents for the treatment of metastatic BC with
standard paclitaxel, given with bevacizumab. The hypothesis, based
on earlier phase II trials, was that one or both of the experimental arms
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Fig 3. Kaplan-Meier plots of progression-free survival (PFS) for the exploratory analyses in patient subgroups of ixabepilone or nab-paclitaxel compared with
paclitaxel, respectively, defined by (A, B) triple-negative disease and (C, D) hormone receptor–positive disease
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similar or reduced toxicity. By using interim analyses for superiority/
futility, we were able to limit the total number of patients required to
assess the primary end point.
Altering the treatment schedule of paclitaxel has been shown to
improve efficacy and reduce toxicity,32 and once-per-week dosing has
become the standard for the treatment of metastatic disease. Random-
ized phase II data suggested superior efficacy from nab-paclitaxel at
150 mg/m2,11 and small phase II studies demonstrated reduced toxic-
ity with ixabepilone once per week.20 By comparing these three micro-
tubule inhibitors by using once-per-week dosing, we hoped to
capitalize on improvements in schedule while assessing the relative
efficacy and toxicity of nab-paclitaxel and ixabepilone compared with
paclitaxel. The bevacizumab backbone reflected the current best treat-
ment for HER2-negative advanced BC when the study was designed.7
In earlier phase II studies, ixabepilone once per week was rela-
tively well tolerated, with less hematologic toxicity than that seen with
dosing once every 3 weeks. Here, however, it was inferior to paclitaxel
for PFS, response, and OS. The overall rates of nonhematologic toxic-
ity were higher, indicating that it would not be possible to overcome
inferior efficacy by increasing ixabepilone dose. Although phase II
studies suggested improved efficacy with higher-dose nab-paclitaxel
given once per week, in this phase III trial, treatment with nab-
paclitaxel resulted in significantly greater hematologic and nonhema-
tologic toxicity compared with paclitaxel, with a trend toward shorter
PFS. Early dose reductions were necessary because of toxicity, but the
dose was generally maintained within the therapeutic range used in
clinical practice.
As noted, virtually all patients received bevacizumab. Usage has
since declined because this agent is no longer labeled for the treatment
of BC in the United States (although it is still approved in other
countries), raising a question regarding the applicability of our results
without bevacizumab. Although an interaction is theoretically possi-
ble, there are no data to indicate that bevacizumab would preferen-
tially synergize with paclitaxel and not with the other agents or that our
results would have been different if bevacizumab had not been in-
cluded in the treatment regimen.
The dose of nab-paclitaxel used in this study is clearly not
feasible, and it resulted in frequent dose reductions and discon-
tinuations. Ongoing trials are evaluating intermediate doses in
biologic subsets such as TN disease, although we did not identify
differential efficacy in our unplanned analysis. Ixabepilone was
approved on the basis of studies that used a once-every-3-weeks
dosing schedule in taxane-resistant disease and, although this re-
sulted in significant toxicity,14-16,27 it remains the standard sched-
ule for ixabepilone use.
In summary, this phase III cooperative group trial failed to dem-
onstrate superiority of either nab-paclitaxel or ixabepilone given once
per week compared with paclitaxel in patients with advanced BC, with
all drugs given in combination with bevacizumab. Both newer agents
were associated with increased overall toxicity, possibly inferior effec-
tiveness, and reduced palliation of disease-related symptoms, even
though earlier studies had suggested that either of the investigational
arms, particularly nab-paclitaxel, might be more efficacious than stan-
dard once-per-week paclitaxel. Without direct evidence, the earlier
trials led to widespread use of more costly and higher-dose nab-
paclitaxel in many clinical practices. The higher dose used in our phase
III trial resulted in early discontinuation and dose reductions, which in
turn limited exposure to the drug. On the basis of our data, once-per-
week paclitaxel should remain the preferred microtubule inhibitor for
treating patients with metastatic BC in the first-line setting, and there
is no evidence that either of the newer agents is superior. Our trial
illustrates the importance of adequately powered prospective trials
to confirm phase II reports. In addition, these results remind
clinicians to be cautious when incorporating new agents, particu-
larly those that are more expensive and potentially more toxic, and
support the cooperative group mechanism for assessing both bet-
ter and less expensive therapies.33
Table 3. Toxicity End Points
Toxicity
Paclitaxel (n  272)
No. (%)
Nab-Paclitaxel (n  263) Ixabepilone (n  239)
No. (%) P No. (%) P
Any grade 3 events 162 (60) 221 (84)  .001 145 (61) .93
Any hematologic adverse events 60 (22) 144 (55)  .001 29 (12) .0037
ANC/AGC 50(18 134 (51)  .001 16 (7)  .001
Leukocytes (total WBC) 21 (8) 48 (18)  .001 9 (4) .037
Hemoglobin 8 (3) 13 (5) .27 8 (3) .80
Any nonhematologic adverse events 134 (49) 170 (65)  .001 138 (58) .17
Sensory neuropathy 48 (18) 70 (27) .016 60 (25) .15
Fatigue (asthenia, lethargy, malaise) 27 (10) 43 (16) .030 35 (15) .22
Hypertension 25 (9) 20 (8) .54 28 (12) .37
Motor neuropathy 9 (3) 26 (10) .0026 17 (7) .066
Pain 12 (4) 25 (10) .026 10 (4) 1.0
Nausea 0 (0) 13 (5)  .001 14 (6)  .001
Maximum grade of sensory neuropathy P† P†
2 77 (28) 73 (28) .01 53 (22) .032
3 47 (17) 67 (25) 54 (23)
4 1 ( 1) 3 (1) 6 (3)
Abbreviations: AGC, absolute granulocyte count; ANC, absolute neutrophil count.
P values are from two-sided Fisher exact tests for patients receiving paclitaxel concurrently enrolled onto each experimental arm.
†P values are from Cochran-Mantel-Haenszel 2 tests for ordinal scale data.
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GLOSSARY TERMS
bevacizumab: also called Avastin (Genentech, South San
Francisco, CA). Bevacizumab is a recombinant, humanized,
monoclonal antibody that binds and neutralizes the vascular en-
dothelial growth factor, thus acting as an antiangiogenic agent.
triple-negative breast cancer (TNBC): breast tumors that are
negative for estrogen and progesterone receptor expression and that also
underexpress HER-neu.
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Methods
Data quality was ensured by a review of the data by the Alliance Statistics and Data Center and by the study chairperson following
Alliance policies. This phase III therapeutic trial was monitored at least twice annually by the Data and Safety Monitoring Board, a standing
committee composed of individuals from within and outside the Alliance.
Table A1. Dose Modifications for Paclitaxel, Nab-Paclitaxel, and Ixabepilone
Dose Level Paclitaxel (mg/m2) Nab-Paclitaxel (mg/m2) Ixabepilone (mg/m2)
0 90 150 16
1 75 120 13
2 60 90 10
NOTE. Chemotherapy was delayed with required dose reduction for absolute neutrophil count (ANC)  1,000 or platelets  75,000 on day 1 of a cycle.
Chemotherapy was skipped for ANC  1,000 and platelets  75,000 on days 8 or 15 with dose reductions required for ANC  1,000 and platelets  100,000.
Chemotherapy was dose-reduced for intolerable grade 2 peripheral neuropathy, held for grade 3 peripheral neuropathy until improvement to grade  2 with
subsequent mandatory dose reduction, and was discontinued for grade 4 peripheral neuropathy. No dose modifications were allowed for bevacizumab. Bevacizumab
was held for uncontrolled hypertension, symptoms of reversible posterior leukoencephalopathy syndrome, venous thromboembolic events, significant proteinuria,
wound dehiscence/perforation, and surgery and was discontinued for grade 4 events and any arterial thromboembolism.
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Table A2. Patient and Tumor Characteristics for Patients Randomly Assigned to Paclitaxel and Ixabepilone Before Closure of the Ixabepilone Arm
Characteristic
Paclitaxel (n  246)
No. (%)
Ixabepilone (n  245)
No. (%) P
Age, years
20-49 60 (24) 73 (30) .20
50-69 159 (65) 154 (63)
70-80 27 (11) 18 (7)
Female sex 243 (99) 243 (99) 1.00
Race/ethnicity
Unknown 4 (2) 3 (1)
White 194 (79) 206 (84) .28
Black 38 (15) 26 (11)
Other 10 (4) 10 (4)
Taxane as adjuvant therapy
Yes 107 (43) 107 (44) 1.00
No 139 (57) 138 (56)
Site of metastases
Unknown 3 (1) 4 (2)
Any visceral 192 (78) 199 (81) .36
Any soft tissue 176 (72) 164 (67) .32
Any bone 144 (59) 163 (67) .06
Disease-free interval
Unknown 0 (0) 4 (2)
0 to  1 month (de novo) 29 (12) 28 (11) .38
 1 month to  2 years 79 (32) 64 (26)
 2 years 138 (56) 149 (61)
Clinical stage
Unknown 21 (9) 30 (12)
III 23 (9) 21 (9) 1.0
IV 202 (82) 194 (79)
Tumor subtype
ER or PgR unknown/missing 0 (0) 4 (2)
ER or PgR positive 182 (74) 176 (72) .84
HER2 missing 5 (2) 3 (1)
HER2 positive 6 (2) 2 (1)
HER2 negative 171 (70) 171 (70)
ER and PgR negative 64 (26) 65 (27)
HER2 missing 0 (0) 0 (0)
HER2 positive 1 ( 1) 2 (1)
HER2 negative 63 (26) 63 (26)
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, progesterone receptor.
P values are from two-sided Fisher exact tests excluding patients for whom factors were unknown.








No. (%) HR 95% CI
(n  275) (n  246) 
No. (%) 95% CI No. (%) 95% CI
Objective response 91 (34) 105 (38) 96 (39) 64 (27)
Complete 6 (2) 11 (4) 9 (4) 2 (1)
Partial 85 (32) 94 (34) 87 (35) 62 (26)
Stable disease 130 (49) 133 (48) 118 (48) 121 (50)
Progressive disease 22 (8) 26 (9) 23 (9) 34 (14)
Unevaluable 24 (9) 11 (4) 9 (4) 22 (9)
Median time to treatment failure, months 5.2 1.37 1.15 to 1.63 6.6 6.8 4.9 1.47 1.22 to 1.77
Median overall survival, months 23.5 1.17 0.92 to 1.63 26.6 27.3 23.6 1.31 1.03 to 1.66
Rate of progression-free survival at 12 months 36% 0.30 to 0.42 45% 0.39 to 0.51 46% 0.39 to 0.52 29% 0.23 to 0.35
In all, 246 patients were randomly assigned to paclitaxel before closure of the ixabepilone arm.
Rugo et al
© 2015 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Table A4. Toxicity End Points for Patients Randomly Assigned to Paclitaxel and Ixabepilone Before Closure of the Ixabepilone Arm
Toxicity
Paclitaxel (n  243)
No. (%)
Ixabepilone (n  239)
No. (%) P
Any grade 3 events 149 (61) 145 (61) .93
Any hematologic adverse events 54 (22) 29 (12) .0037
ANC/AGC 45 (19) 16 (7)  .001
Leukocytes (total WBC) 21 (9) 9 (4) .037
Hemoglobin 7 (3) 8 (3) .80
Any nonhematologic adverse events 125 (51) 138 (58) .17
Sensory neuropathy 47 (19) 60 (25) .15
Fatigue (asthenia, lethargy, malaise) 26 (11) 35 (15) .22
Hypertension 22 (9) 28 (12) .37
Motor neuropathy 8 (3) 17 (7) .066
Pain 11 (5) 10 (4) 1.0
Nausea 0 (0) 14 (6)  .001
Maximum sensory neuropathy grade P†
2 66 (27) 53 (22) .032
3 46 (19) 54 (23)
4 1 ( 1) 6 (3)
Abbreviations: AGC, absolute granulocyte count; ANC, absolute neutrophil count.
P values are from two-sided Fisher exact tests.
†P value is from Cochran-Mantel-Haenszel 2 tests for ordinal scale data.
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